All patients
critical disease severe disease
sarilumab in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
0.59 [0.23 ; 1.51 ] CORIMUNO-SARI-1 (non ICU), 2021 1 0% 144 NA not evaluable deathsdetailed results CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
0.89 [0.52 ; 1.53 ] CORIMUNO-SARI-1 (non ICU), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 3 0% 644 moderate not evaluable clinical deteriorationdetailed results CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
1.01 [0.48 ; 2.12 ] CORIMUNO-SARI-1 (non ICU), 2021 1 0% 144 NA not evaluable clinical improvementdetailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
1.03 [0.75 ; 1.41 ] Lescure (Sarilumab 200mg), 2021 1 0% 247 NA not evaluable clinical improvement (time to event analysis only)detailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.09 [0.87 ; 1.35 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 506 moderate not evaluable death or ventilationdetailed results CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
1.12 [0.56 ; 2.22 ] CORIMUNO-SARI-1 (non ICU), 2021 1 0% 144 NA not evaluable serious adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
1.26 [0.82 ; 1.94 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 502 moderate not evaluable adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
1.13 [0.77 ; 1.67 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 502 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2025-10-31 19:01 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 553,628,646,645
- roots T: 290
